Technical information and posters

• G-001 Glass Transition Temperature of Cellulose Derivatives by TMA Method
• G-002 Film Properties of HPMC and MC
• G-003 Molecular Weight and Degree of Polymerization of HPMC
• G-004 Cloud Points of Aqueous Solution of Water-Soluble Cellulose Ethers
• G-005 Equilibrium Moisture Content of Water-Soluble Cellulose Ethers
• G-006 Calculation of Molar Substitution from Chemical Analysis
• G-007 Stability of Cellulose Products
• G-008 Maximum Pharmaceutical Daily Dose Approved in Japan
• G-009 Density of Solution for Viscosity Measurement
• G-010 Formulation of McIlvaine's Buffer and Clark-Lubs' Buffer Solutions
• G-011 Film and Other Properties of Low-Viscosity Grade Cellulose Derivatives
• G-012 Biological Oxygen Demand of Methylcellulose (MC) and Hypromellose (HPMC)
• G-013 Maximum potency of inactive ingredients approved in USA
• G-014 Test Fluids for Disintegration and Dissolution Tests for Enteric-Coated Tablets
• G-015 Solubility of Cellulose Derivatives in Mixed Organic Solvents
• G-016 Oxygen Permeability of Low-Viscosity Grade Cellulose Derivatives
• G-017 Glass Transition Temperature of Cellulose Derivatives by DSC Method
• G-018 Glass transition temperature of Hypromellose
• G-019 Peroxide in Pharmaceutical Excipients
• G-020 Evaluation of Anthrone Reaction as an Assay Method for HME CleanerPlus in Cleaning Validation

PageTop

• A-001 Aqueous Dispersion Coating Using Shin-Etsu AQOAT^® -Preparation of Coating Solution-
• A-002 Aqueous Dispersion Coating Using Shin-Etsu AQOAT^® (Tablet Batch Size of 5-100 kg)
• A-003 Examples of Aqueous Dispersion Coating Using Shin-Etsu AQOAT^®: Granule Coating (Batch Size 1.5 kg)
• A-004 Enteric Coating with Shin-Etsu AQOAT^® (HPMCAS) by Using Water-Ethanol Solution
• A-005 Minimum Film Formation Temperature of Shin-Etsu AQOAT^®
• A-006 Aqueous Dispersion Coating Using Shin-Etsu AQOAT^® -Tablet Batch Size of 300 g Using Small Equipment-
• A-007 Molecular Weight of Shin-Etsu AQOAT^® (HPMCAS)
• A-008 Aqueous Enteric Coating with Shin-Etsu AQOAT^® Ammonia-Neutralized Method - Part 1: Solution and Film Properties
• A-009 Stability of Shin-Etsu AQOAT^® at High Temperatures
• A-010 Stability of Shin-Etsu AQOAT^® at High Temperatures (2)
• A-011 Dust Explosivity and Electrostaticity of Shin-Etsu AQOAT^®
• A-012 Aqueous Enteric Coating with Shin-Etsu AQOAT^® Ammonia-Neutralized Method - Part 2: Examples of Coating Applications
• A-013 Aqueous Enteric Coating with Shin-Etsu AQOAT^® Ammonia-Neutralized Method - Part 3: Stability of the Coated Preparations
• A-014 Influence of Alcohol on Gastric Resistance of HPMCAS
• A-015 Enteric-coated Pellets Using Shin-Etsu AQOAT^®(HPMCAS) to Be Incorporated in Tablets
• A-016 Film Solubility of Shin-Etsu AQOAT^® (HPMCAS) in Various Buffers
• A-017 Effect of Hot-melt Extrusion on the Physicochemical Properties of Shin-Etsu AQOAT^® (HPMCAS)
• A-018 Solid Dispersions using Shin-Etsu AQOAT^® (HPMCAS) by Hot-melt Extrusion
• A-019 Explosivity Risk Assessment of the Dry Coating Process Using Shin-Etsu AQOAT^® (HPMCAS)
• A-020 Bibliography / HPMCAS (Shin-Etsu AQOAT^®)
• A-021 Solubility of Shin-Etsu AQOAT^® in Alkali Solutions -For Cleaning Media after Coating Operations-
• A-022 Application of Shin-Etsu AQOAT^®(HPMCAS) to Enteric Coating of Pancreatin Pellets (1)
• A-023 Application of Shin-Etsu AQOAT^®(HPMCAS) to Enteric Coating of Pancreatin Pellets (2)
• A-024 Shin-Etsu AQOAT^®: Innovative Aqueous Enteric Coating Technique Using a Dual-feed Concentric Nozzle.
• A-025 Infrared spectra of Shin-Etsu AQOAT^®(HPMCAS)
• A-026 Particle Size Measurement by Laser Diffraction Method
• A-027 Stability of Shin-Etsu AQOAT^® in various organic solvents
• A-028 Application of Shin-Etsu AQOAT^® (HPMCAS) as a carrier in solid dispersion
• A-029 Enteric Coating of Hard Gelatin Capsules Using Shin-Etsu AQOAT^®
• A-030 Toxicological information of hypromellose acetate succinate
• A-031 Enteric coating of omeprazole granules using Shin-Etsu AQOAT^®
• A-032 Effect of substitution of Shin-Etsu AQOAT^® (HPMCAS) on dissolution profile of Nifedipine solid dispersions prepared by melt extrusion
• A-033 Aqueous Dispersion Coating Using Shin-Etsu AQOAT^® Granule Coating (Batch Size 1.0 kg) by bottom spray method
• A-034 Solid Dispersion of Ibuprofen with Shin-Etsu AQOAT^® from Hot Melt Extrusion
• A-035 Solubility of Shin-Etsu AQOAT^® in mixed organic solvents
• A-036 Taste masked coated pellets and ODT formulation
• A-037 Partially neutralized coating technique using Shin-Etsu AQOAT^®
• A-038 Aqueous Dispersion Coating Using Shin-Etsu AQOAT^® Granule Coating (Batch Size 10 kg) by bottom spray method
• A-039 Stability of Shin-Etsu AQOAT^® ammonia-neutralized solution
• A-040 Dry Powder Coating Using Shin-Etsu AQOAT^® - Basics of Film Formation -
• A-041 Dry Powder Coating Using Shin-Etsu AQOAT^® - Pellet Coating Using Wurster Column(GPCG-1) -
• A-042 Dry Powder Coating Using Shin-Etsu AQOAT^® - Tablet Coating Using Ventilated Pan Coater(HC-130) -
• A-043 Aqueous Enteric Coating for Soft Gelatin Capsule Using Shin-Etsu AQOAT^®
• A-044 Aqueous Fine Particle Coating with Angled Spray
• A-045 Dissolution Behavior of Coated Fine Particles by Aqueous and Solvent Coating
• A-046 Bibliography 2 / HPMCAS (Shin-Etsu AQOAT^®)
• A-047 Minimum Film Formation Temperature of Shin-Etsu AQOAT^®(2)
• A-048 Taste Masking of Coated Fine Particles by Aqueous and Solvent Coating
• A-049 Aqueous Enteric Formulation of Shin-Etsu AQOAT^® Containing Amino Acid as a Stabilizer
• A-051 Nifedipine Solid Dispersion using Shin-Etsu AQOAT^®-Preparation by HME and Downstream Processing
• A-052 Stability of Shin-Etsu AQOAT^® under Humid Storage Conditions
• A-053 Aqueous Enteric Formulation of Shin-Etsu AQOAT^® Containing Amino Acid as a Stabilizer for Mini-tablets
• A-054 IR spectrums of HPMCP and Shin-Etsu AQOAT^®
• A-055 Aqueous Formulation of Shin-Etsu AQOAT^® Containing an Amino Acid as Stabilizer -Comparison of Formulation and Process Parameters on Different Coating Equipment-
• A-056 Comparison of Mini-Tablet Enteric Coating with Shin-Etsu AQOAT^® using Perforated Pan or Fluid Bed Coating Equipment
• A-057 Triacetin as an Alternative Plasticizer for Aqueous Dis-persion Coating with Shin-Etsu AQOAT^®
• A-058 Solution preparation of HPMCP and Shin-Etsu AQOAT^®

PageTop

• L-001 Particle Size Measurement by Laser Diffraction Method
• L-002 Swelling of L-HPC in Various Test Media
• L-003 Formulation Example: Ginkgo Extract Tablets Using L-HPC
• L-004 Dust Explosivity and Electrostaticity of L-HPC
• L-005 Dry Compaction Using L-HPC
• L-006 Bilayer Tablets Using L-HPC and METOLOSE^® SR
• L-007 Bibliography / L-HPC
• L-008 Orally Disintegrating Tablets Using L-HPC
• L-009 CapsuleFiller
• L-010 Roller compaction using L-HPC
• L-011 Pellet extrusion - spheronization using L-HPC
• L-012 Differences in wet granulation processing using L-HPC
• L-013 Toxicological information of Low-substituted hydroxypropyl cellulose
• L-014 Effects of the added water quantity to the tablet properties at wet granulation process with L-HPC
• L-015 Pellets preparation by drug layering using L-HPC
• L-016 Orally disintegrating tablets using L-HPC(NBD grades)
• L-017 Particle size analysis of L-HPC with various particle size analyzers
• L-018 Water Binding Capability of L-HPC in Wet Granulation
• L-019 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Particle Attributes-
• L-020 Comparative study of various L-HPC for paracetamol 500 mg tablets-Hydroxypropyl content -
• L-021 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Internal Addition and Particle Attributes-
• L-022 Comparative Study of Various L-HPC for Paracetamol 500 mg Tablets-Roller compaction-
• L-023 Improvement of Dissolution from Tablet Containing Herbal Medicine using L-HPC
• L-024 Minitablets using L-HPC
• L-025 Bibliography 2 / L-HPC
• L-026 Super-High Speed Direct Compression using SmartEx^®
• L-027 Super-High Speed Direct Compression using L-HPC NBD
• L-028 Twin screw granulation using L-HPC
• L-029 The Effect of a Glidant on L-HPC
• L-030 The Effect of a Glidant on L-HPC for dry granulation
• L-031 Change of swelling performance of disintegrants after wet granulation
• L-032 Influence of tablet shape on capping tendency
• L-033 IR spectrums of L-HPC and SmartEx^®
• L-034 Tablet Weight Deviation and Content Uniformity of Tablets Prepared by Direct Compression Using SmartEx^®
• L-035 Disintegration, Tablet Weight Deviation and Content Uniformity of Tablets Prepared by Direct Compression Using SmartEx^®
• L-036 High API Dose Tablet with SmartEx^® and Additional L-HPC

PageTop

• H-001 HPMCP - Typical Coating Conditions for Tablets
• H-002 HPMCP - Typical Coating Conditions for Granules (1)
• H-003 HPMCP - Typical Coating Conditions for Granules (2)
• H-004 Film Solubility of HPMCP in Various Buffers
• H-005 Hydrolysis of HPMCP in Water-Ethanol Solution
• H-006 Enteric Coating of Hard Gelatin Capsules Using HPMCP
• H-007 Residual Solvent in Water/Ethanol HP-55 Tablet Coating
• H-008 Molecular Weight of HPMCP
• H-009 Toxicological information of hypromellose phthalate
• H-010 Solubility of HPMCP in mixed organic solvents
• H-011 Film Solubility of Mixed HPMCP
• H-012 Solvent Coating for Fine Particle with Angled Spray
• H-013 Dissolution Behavior of Coated Fine Particles by Aqueous and Solvent Coating
• H-014 Taste Masking of Coated Fine Particles by Aqueous and Solvent Coating
• H-015 Stability of HPMCP Coated Tablets
• H-016 Stability of HPMCP under Humid Storage Conditions
• H-017 IR spectrums of HPMCP and Shin-Etsu AQOAT^®
• H-018 Enteric Coating of Soft Gelatin Capsules with Hypromellose Phthalate (HPMCP)
• H-019 Solution preparation of HPMCP and Shin-Etsu AQOAT^®

PageTop

• SR-001 Comparison between Direct Compression and Wet Granulation in Hydrophilic Matrix Tablets Using METOLOSE^® SR
• SR-002 Sustained Release of Naproxen Using METOLOSE^® SR
• SR-003 Solvent Selection in Wet Granulation for Hydrophilic Matrix Tablets Using METOLOSE^® SR
• SR-004 Formulation Example: Lithium Carbonate Extended-Release Tablet Using METOLOSE^® SR
• SR-005 Bilayer Tablets Using L-HPC and METOLOSE^® SR
• SR-006 A Study on the Robustness of the Wet Granulation Process to Prepare Metformin HCl Extended-Release Matrix Tablets using METOLOSE^® 90SH-15000SR
• SR-007 The effect of the solubility of APIs on the dissolution profiles of hydrophilic matrix tablets containing METOLOSE^® SR
• SR-008 The effect of CMCNa on the dissolution profiles of hydrophilic matrix tablets containing METOLOSE^® SR
• SR-009 QbD (Quality by design) approach to the formulation of hydrophilic matrix tablets using METOLOSE^® SR
• SR-010 Particle Size Analysis of METOLOSE^® SR with Various Laser Analyzers
• SR-011 QbD (Quality by Design) Approach to the Formulation of Hydrophilic Matrix Tablets using METOLOSE^® SR
• SR-012 Comparative Study of Dissolutions from Matrix Tablets with METOLOSE^® SR by Different Preparation Methods
• SR-013 Particle Size Distribution of METOLOSE^® SR
• SR-014 QbD (Quality by Design) Approach for the Formulation of Hydrophilic Matrix Tablets using METOLOSE^® SR
• SR-015 The Effect of a Glidant of Hydrophilic Matrix Tablets Containing METOLOSE^® SR
• SR-016 METOLOSE^® SR in 500 mg Metformin HCl Extended Release Tablets: Simulation of High Speed Compaction

PageTop

• M-001 Adjusting Viscosity by Blending Two Grades of METOLOSE^®
• M-002 METOLOSE^® SM-4 for Pellet Film Coating
• M-003 Taste Masking of Fine Granules by METOLOSE^® SM-4 and an Acrylic Polymer
• M-004 Solubility of HPMC and MC (15 mPa•s) to Organic Solvents
• M-005 Toxicological information of Methylcellulose
• M-006 Toxicological information of Hypromellose
• M-007 High gloss coating formulation using METOLOSE^®
• M-008 IR spectrums of METOLOSE^® and Pharmacoat^®

PageTop

• P-001 Growth of Microorganisms in Aqueous Solution of PHARMACOAT^®
• P-002 Stability of PHARMACOAT^® Solution in Sterilization
• P-003 Filtration of PHARMACOAT^® Solutions
• P-004 Solubility of PHARMACOAT^® 606 in Alcohol-Water Mixtures
• P-005 Effect of Moisture Content on the Mechanical Properties of Cast HPMC Films
• P-006 Color Coating with PHARMACOAT^®
• P-007 Timed-release Coating with PHARMACOAT^® and Shin-Etsu AQOAT^® for Taste-masking Effect
• P-008 Effect of plasticizers and other additives on the mechanical properties of cast hypromellose films
• P-009 An organic coating method with Pharmacoat^® -With mixed solvent of high content of ethanol and water-
• P-010 Application of Pharmacoat^® (Hypromellose, HPMC) as a carrier in solid dispersion
• P-011 A coating technique for high-friability tablets using Pharmacoat^®
• P-012 An advanced coating formulation with PVA and HPMC
• P-013 Coating Formulation for Logo Tablets
• P-014 Dissolution behavior of various lower viscosity grades
• P-015 IR spectrums of METOLOSE^®and Pharmacoat^®
• P-016 Solubility of PHARMACOAT^® 606 in Acetone/Water Mixtures

PageTop

• PBP16-1 Functional Cellulose Derivatives for Mini Tablets

PageTop

• AAPS16-1 The study on swelling properties of various L-HPC
• AAPS16-2 Super-High Speed Direct Compression Using SmartEx^®
• AAPS16-3 Improvement of Drug Release from Hard Capsules Using L-HPC as a Filler
• AAPS16-4 Functional Cellulose Derivatives for Mini Tablets
• AAPS16-5 Nifedipine Solid Dispersion Using AQOAT^® HPMCAS: Preparation by HME and Downstream Processing
• AAPS16-6 Investigation of the Effect of Substituent Groups of HPMCAS on Drug Crystallization Inhibition
• AAPS16-7 Physical Stability of Amorphous Solid Dispersion Prepared from Melt-Extrusion Process Using Hypromellose Acetate Succinate

PageTop

• AAPS17-1 Direct Compaction of Hypromellose acetate succinate (HPMCAS) based amorphous solid dispersion prepared by hot melt extrusion technology
• AAPS17-2 Particle shape analysis of L-HPC by dynamic image analysis and its influence on physical properties
• AAPS17-3 Investigation of user friendly enteric coating formulation using hypromellose acetate succinate (HPMCAS)
• AAPS17-4 The effect of substitution type and drying conditions on the physical properties of HPMC films
• AAPS17-5 Content uniformity on the tablets prepared by direct compression
• AAPS17-6 Enteric coating of mini tablets using AQOAT HPMCAS-process comparison between performed pan and wurster coating

PageTop

• PBP18-1 Release of Itraconazole from HPMCAS solid dispersions
• PBP18-2 Variation of metformin HCL quality and the effect on extended release matrix tablets

PageTop

• EuPFi18-1 Taste masking coating of mini-tablets with cellulose derivertives: formulation and analytical challenges

PageTop

• AAPS18-1 Advantage of various pellet coating techniques using hypromellose acetate succinate (HPMCAS)
• AAPS18-2 Evaluation of HPMCAS-nifedipine solid dispersion by DSC, XRD and their hyphenated analysis
• AAPS18-3 Development and evaluation of dry enteric coating approach for lansoprazole delayed release pellets using Hypromellose Acetate Succinate (HPMCAS)

PageTop